Polycystic ovary syndrome throughout a woman’s life

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged women and the main cause of infertility due to anovulation. However, this syndrome spans the lives of women affecting them from in-utero life until death, leading to several health risks that can impair quality of life and increase morbidity and mortality rates. Fetal programming may represent the beginning of the condition characterized by hyperandrogenism and insulin resistance which leads to a series of medical consequences in adolescence, adulthood, and old age. Menstrual and fertility problems evolve into metabolic complications as age advances. An early and precise diagnosis is important for an adequate management of PCOS, especially at the extreme ends of the reproductive lifespan. However, many different phenotypes are included under the same condition, being important to look at these different phenotypes separately, as they may require different treatments and have different consequences. In this way, PCOS exhibits a great metabolic complexity and its diagnosis needs to be revised once again and adapted to recent data obtained by new technologies. According to the current medical literature, lifestyle therapy constitutes the first step in the management, especially when excess body weight is associated. Pharmacotherapy is frequently used to treat the most predominant manifestations in each age group, such as irregular menses and hirsutism in adolescence, fertility problems in adulthood, and metabolic problems and risk of cancer in old age. Close surveillance is mandatory in each stage of life to avoid health risks which may also affect the offspring, since fetal and post-natal complications seem to be increased in PCOS women.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Solomon CG. Polycystic ovary syndrome. N Engl J Med. 2016;375:54–64.

    Article  Google Scholar 

  2. 2.

    Stein IF, Levethal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181–91.

    Article  Google Scholar 

  3. 3.

    Zawadzki JK, Dunaif A. Diagnosis criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, et al., editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992. p. 377–84.

    Google Scholar 

  4. 4.

    Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.

    Article  Google Scholar 

  5. 5.

    Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88.

    PubMed  Article  Google Scholar 

  6. 6.

    National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome. December 3–5, 2012. Executive summary. Available at https/prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accesed March 1, 2017.

  7. 7.

    Ning N, Balen A, Brezina PR, et al. How to recognize PCOS: results of a web-based survey at IVF-worldwide.com. Reprod BioMed Online. 2013;26:500–5.

    PubMed  Article  Google Scholar 

  8. 8.

    Dewailly D. Diagnostic criteria for PCOS: is there a need for a rethink? Best Pract Res Clin Obstet Gynaecol. 2016;37:5–11.

    PubMed  Article  Google Scholar 

  9. 9.

    Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Androgen Excess and PCOS Society Disease State Clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome- part 1. Endocr Pract. 2015;21:1291–300.

    PubMed  Article  Google Scholar 

  10. 10.

    Zhu RY, Wong YC, Yong EL. Sonographic evaluation of polycystic ovaries. Best Pract Res Clin Obstet Gynaecol. 2016;35:25–37.

    Article  Google Scholar 

  11. 11.

    Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95:4399–405.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26:3123–9.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006;91:3922–7.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Stein S, Jennifer L, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril. 2016;106:16–24.

    Article  Google Scholar 

  15. 15.

    Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27:3067–73.

    PubMed  Article  Google Scholar 

  16. 16.

    Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med. 2014;62:868–74.

    PubMed  Article  Google Scholar 

  17. 17.

    Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril. 2016;106:948–58.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Franks S, Mc Carthy M, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29:278–85.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14:38.

    PubMed  PubMed Central  Article  Google Scholar 

  20. 20.

    De Melo AS, Dias SV, De Carvalho R, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150:11–24.

    Article  CAS  Google Scholar 

  21. 21.

    Longo S, Bollani L, Decembrino L, Di Comite A, Angelini M, Stronati M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J Matern Fetal Neonatal Med. 2013;26:222–5.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet 2017.

  23. 23.

    Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod. 2002;17:2573–9.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17–33.

    PubMed  Article  Google Scholar 

  25. 25.

    Voulgaris N, Papanastasiou L, Piaditis G, et al. Vitamin D and aspects of female fertility. Hormones (Athens). 2017;16:5–21.

    Google Scholar 

  26. 26.

    Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism of hyperandrogenemia and IR. Fertil Steril. 2008;89:1039–48.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Krishnan A, Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism. J Endocrinol. 2017;232:R99–R113.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33:981–1030.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Ibáñez L, Jaramillo A, Enríquez G, et al. Polycystic ovaries after precocious pubarche: relation to prenatal growth. Hum Reprod. 2007;22:395–400.

    PubMed  Article  Google Scholar 

  30. 30.

    Ibáñez L, Díaz R, López-Bermejo A, Marcos MV. Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism. Rev Endocr MetabDisord. 2009;10:63–76.

    Article  Google Scholar 

  31. 31.

    Idkowiak J, Lavery GG, Dhir V, et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol. 2011;165:189–207.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril. 2011;95:727–30.

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011;96:E1262–7.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Rosenfield RL. Identifying children at risk of polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:787–96.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Marsh CA, Grimstad FW. Primary amenorrhea: diagnosis and management. Obstet Gynecol Surv. 2014;69:603–12.

    PubMed  Article  Google Scholar 

  36. 36.

    Witchel SF, Oberfield S, Rosenfield RL, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr. 2015;87:376–89.

    Article  CAS  Google Scholar 

  37. 37.

    Glueck CJ, Woo JG, Khoury PR, Morrison JA, Daniels SR, Wang P. Adolescent oligomenorrhea (age 14–19) tracks into the third decade of life (age 20–28) and predicts increased cardiovascular risk factors and metabolic syndrome. Metabolism. 2015;64:539–53.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203:201.e1–5.

    Article  Google Scholar 

  39. 39.

    Fruzzetti F, Campagna AM, Perini D, Carmina E. Ovarian volume in normal and hyperandrogenic adolescent women. FertilSteril. 2015;104:196–9.

    CAS  Google Scholar 

  40. 40.

    Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95:4965–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Welt CK, Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013;98:4629–38.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Fauser BC, Tarlatzis RW, Rebar RS, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.e25.

    PubMed  Article  Google Scholar 

  43. 43.

    Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Tsikouras P, Spyros L, Manav B, et al. Features of polycystic ovary syndrome in adolescence. J Med Life. 2015;8:291–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015;4:CD010334.

    Google Scholar 

  46. 46.

    Buggs C, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinol MetabClin North Am. 2005;34:677.

    Article  Google Scholar 

  47. 47.

    Bhattacharya SM, Jha A, DasMukhopadhyay L. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome. Int J Gynaecol Obstet. 2016;132:210–3.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril. 2009;92:626–34.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    de Zegher F, Ibáñez L. Therapy: low-dose flutamide for hirsutism: into the limelight, at last. Nat Rev Endocrinol. 2010;6:421–2.

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, del Río L, de Zegher F. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol. 2009;71:351–7.

    Article  CAS  Google Scholar 

  51. 51.

    Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32:1075–91.

    PubMed  Article  Google Scholar 

  52. 52.

    Michelmore KF, Balen AH, Dunger DB, et al. Polycystic ovaries and eating disorders: are they related? Hum Reprod. 2001;16:765–9.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Bachelot A. Polycystic ovarian syndrome: clinical and biological diagnosis. Ann Biol Clin (Paris). 2016;74:661–7.

    Google Scholar 

  54. 54.

    Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011;7:CD007506.

    Google Scholar 

  55. 55.

    Radon PA, McMahon MJ, Meyer WR. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol. 1999;94:194–7.

    CAS  PubMed  Google Scholar 

  56. 56.

    Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;21:560–74.

    PubMed  Article  Google Scholar 

  57. 57.

    Qublan HS, Yannakoula EK, Al-Qudah MA, El-Uri FI. Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. Saudi Med J. 2007;28:1694–9.

    PubMed  Google Scholar 

  58. 58.

    Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21:80–9.

    PubMed  Article  Google Scholar 

  59. 59.

    Karimzadeh MA, Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril. 2010;94:216–20.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Domecq JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98:4655–63.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med. 2014;370:2002–13.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. 62.

    Malik SM, Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes. 2012;3:71–9.

    PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Johansson K, Cnattingius S, Näslund I, et al. Outcomes of pregnancy after bariatric surgery. N Engl J Med. 2015;372:814–24.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687–708.

    PubMed  Article  Google Scholar 

  65. 65.

    Mihailidis J, Dermesropian R, Taxel P, Luthra P, Grant-Kels JM. Endocrine evaluation of hirsutism. Int J Womens Dermatol. 2017;3(1 Suppl):S6–S10.

    PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Homburg R, Insler V. Ovulation induction in perspective. Hum Reprod Update. 2002;8:449–62.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;16(5):CD003053.

    Google Scholar 

  68. 68.

    Huang X, Wang P, Tal R, Lv F, Li Y, Zhang X. A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. Int J Gynaecol Obstet. 2015;131:111–6.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Goodman NF, Cobin RH, Futterweit W, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015;21:1415–26.

    PubMed  Article  Google Scholar 

  70. 70.

    Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77:91–7.

    PubMed  Article  Google Scholar 

  71. 71.

    Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-estrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009;4:CD002249.

    Google Scholar 

  72. 72.

    Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril. 2004;81:1187–93.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–77.

    Article  Google Scholar 

  74. 74.

    Legro RS, Brzysli RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119–29.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  75. 75.

    Wang R, Kim B, van Wely M, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017;356:j138.

    PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (Sao Paulo). 2015;70:765–9.

    Article  Google Scholar 

  77. 77.

    Homburg R. Choices in the treatment of anovulatory PCOS. Current management of polycystic ovary syndrome. London: RCOG Press; 2010. p. 143–52.

    Book  Google Scholar 

  78. 78.

    Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2015;100:1742–7.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–9.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Biljan MM, Hemmings R, Brassard N. The outcome of 150 babies following the treatment with Letrozole or Letrozole and gonadotropins. Fertil Steril. 2005;84:S95.

    Article  Google Scholar 

  81. 81.

    Committee Opinion No. 663 Summary: Aromatase Inhibitors in Gynecologic Practice. Obstet Gynecol. 2016. https://doi.org/10.1097/AOG.0000000000001478.

  82. 82.

    Orvieto R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril. 2009;91:1533–5.

    CAS  PubMed  Article  Google Scholar 

  83. 83.

    Calaf Alsina J, Ruiz Balda JA, Romeu Sarrió A, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial. BJOG. 2003;110:1072–7.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Weiss NS, Nahuis M, Bayram N, Mol BW, Van der Veen F, van Wely M. Gonadotropins for ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst Rev. 2015;9:CD010290.

    Google Scholar 

  85. 85.

    Lin H, Li Y, Li L, Wang W, Yang D, Zhang Q. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs PLoS One. 2014;9:e91796.

    PubMed  Article  CAS  Google Scholar 

  86. 86.

    Hueb CK, Dias Junior JA, Abrão MS, Filho EK. Drilling: medical indications and surgical technique. Rev Assoc Med Bras. 2015;61:530–5.

    PubMed  Article  Google Scholar 

  87. 87.

    Youssef H, Atallah MM. Unilateral ovarian drilling in polycystic ovarian syndrome: a prospective randomized study. Reprod BioMed Online. 2007;15:457–62.

    PubMed  Article  Google Scholar 

  88. 88.

    Lebbi I, Ben Temime R, Fadhlaoui A, Feki A. Ovarian drilling in PCOS: is it really useful? Front Surg. 2015;2:30.

    PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Birch Petersen K, Pedersen NG, Pedersen AT, Lauritsen MP, la CourFreiesleben N. Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction. Reprod BioMed Online. 2016;32:563–83.

    PubMed  Article  Google Scholar 

  90. 90.

    Wiser A, Shalom-Paz E, Reinblatt SL, Holzer H, Tulandi T. Controlled ovarian hyperstimulation in women with polycystic ovarian syndrome with or without intrauterine insemination. Gynecol Endocrinol. 2012;28:502–4.

    CAS  PubMed  Article  Google Scholar 

  91. 91.

    Heijnen EM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13–21.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Sahu B, Ozturk O, Ranierri M, Serhal P. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome. Arch Gynecol Obstet. 2008;277:239–44.

    PubMed  Article  Google Scholar 

  93. 93.

    Munné S, Dailey T, Sultan KM, Grifo J, Cohen J. The use of first polar bodies for preimplantation diagnosis of aneuploidy. Hum Reprod. 1995;10:1014–20.

    PubMed  Article  Google Scholar 

  94. 94.

    Gianaroli L, Magli MC, Ferraretti AP, Lappi M, Borghi E, Ermini B. Oocyte euploidy, pronuclear zygote morphology and embryo chromosomal complement. Hum Reprod. 2007;22:241–9.

    CAS  PubMed  Article  Google Scholar 

  95. 95.

    Weghofer A, Munne S, Chen S, Barad D, Gleicher N. Lack of association between polycystic ovary syndrome and embryonic aneuploidy. Fertil Steril. 2007;88:900–5.

    PubMed  Article  Google Scholar 

  96. 96.

    Wood JR, Dumesic DA, Abbott DH, Strauss JF III. Molecular abnormalities inoocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab. 2007;92:705–13.

    CAS  PubMed  Article  Google Scholar 

  97. 97.

    Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10:e31–21.

    Article  Google Scholar 

  98. 98.

    Nejad ES, Saedi T, Saedi S, Rashidi BH, Nekoo ZA, Jahangiri N. Comparison of in vitro fertilisation success in patients with polycystic ovary syndrome and tubal factor. Gynecol Endocrinol. 2011;27:117–20.

    PubMed  Article  Google Scholar 

  99. 99.

    Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH. Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in-vitro fertilisation treatment. J Assist Reprod Genet. 2014;31:205–11.

    PubMed  Article  Google Scholar 

  100. 100.

    McCormick B, Thomas M, Maxwell R, Williams D, Aubuchon M. Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index. Fertil Steril. 2008;90:2304–9.

    PubMed  Article  Google Scholar 

  101. 101.

    Bellver J, Martinez-Conejero JA, Labarta E, et al. Endometrial gene expression in the window of implantation is altered in obese women especially in association with polycystic ovary syndrome. Fertil Steril. 2011;95:2335–41.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Fong SA, Palta V, Oh C, Cho MM, Loughlin JS, McGovern PG. Multiple pregnancy after gonadotropin-intrauterine insemination: an unavoidable event? Obstet Gynecol. 2011;2011:465483.

    Google Scholar 

  103. 103.

    Harbottle S, Hughes C, Cutting R, Roberts S, Brison D. Association of Clinical Embryologists & the (ACE) British Fertility Society (BFS). Elective single embryo transfer: an update to UK best practice guidelines. Hum Fertil (Camb). 2015;18:165–83.

    Article  Google Scholar 

  104. 104.

    Fatemi HM, Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil Steril. 2015;103:870–3.

    CAS  PubMed  Article  Google Scholar 

  105. 105.

    Garcia-Velasco JA. Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. Fertil Steril. 2012;97:527–8.

    PubMed  Article  Google Scholar 

  106. 106.

    Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.

    PubMed  Google Scholar 

  107. 107.

    Kollmann M, Klaritsch P, Martins WP, et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Hum Reprod. 2015;30:2396–403.

    CAS  PubMed  Article  Google Scholar 

  108. 108.

    Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21:575–92.

    PubMed  Article  Google Scholar 

  109. 109.

    Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:673–83.

    CAS  PubMed  Article  Google Scholar 

  110. 110.

    Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204:558.e1–6.

    Article  Google Scholar 

  111. 111.

    Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol. 2013;11:56.

  112. 112.

    Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). HumReprod. 2012;27:14–24.

    Google Scholar 

  113. 113.

    Sterling L, Liu J, Okun N, Sakhuja A, Sierra S, Greenblatt E. Pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril. 2016;105:791–7.e2.

    PubMed  Article  Google Scholar 

  114. 114.

    Palomba S, Falbo A, Chiossi G, et al. Low-grade chronic inflammation in pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. J Clin Endocrinol Metab. 2014;99:2942–51.

    CAS  PubMed  Article  Google Scholar 

  115. 115.

    Maliqueo M, SundströmPoromaa I, Vanky E, et al. Placental STAT3 signaling is activated in women with polycystic ovary syndrome. Hum Reprod. 2015;30:692–700.

    CAS  PubMed  Article  Google Scholar 

  116. 116.

    Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. 2011;343:d6309.

    PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Naver KV, Grinsted J, Larsen SO, et al. Increased risk of preterm delivery and pre-eclampsia in women with polycystic ovary syndrome and hyperandrogenaemia. BJOG. 2014;121:575–81.

    CAS  PubMed  Article  Google Scholar 

  118. 118.

    Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99:447–52.

    Article  CAS  Google Scholar 

  119. 119.

    Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95:448–55.

    Article  CAS  Google Scholar 

  120. 120.

    Feng L, Lin XF, Wan ZH, Hu D, Du YK. Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2015;31:833–9.

    CAS  PubMed  Article  Google Scholar 

  121. 121.

    van der Spuy Z, Dyer S. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:755–71.

    PubMed  Article  Google Scholar 

  122. 122.

    Joham AE, Boyle JA, Ranasinha S, Zoungas S, Teede HJ. Contraception use and pregnancy outcomes in women with polycystic ovary syndrome: data from the Australian Longitudinal Study on Women's Health. Hum Reprod. 2014;29:802–8.

    CAS  PubMed  Article  Google Scholar 

  123. 123.

    Wang Q, Luo L, Lei Q, et al. Low aneuploidy rate in early pregnancy loss abortuses from patients with polycystic ovary syndrome. Reprod BioMed Online. 2016;33:85–92.

    PubMed  Article  Google Scholar 

  124. 124.

    Løvvik TS, Wikström AK, Neovius M, Stephansson O, Roos N, Vanky E. Pregnancy and perinatal outcomes in women with polycystic ovary syndrome and twin births: a population-based cohort study. BJOG. 2015;122:1295–302.

    PubMed  Article  Google Scholar 

  125. 125.

    Han AR, Kim HO, Cha SW, et al. Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome: a case-control study. Clin Exp Reprod Med. 2011;38:103–8.

    PubMed  PubMed Central  Article  Google Scholar 

  126. 126.

    Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  127. 127.

    Winter S, Talbott E, Guzick D, Zborowski J, McHugh K. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril. 2000;73:724–7229.

    Article  Google Scholar 

  128. 128.

    Brown ZA, Louwers YV, Fong SL. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril. 2011;96:1259–65.

    PubMed  Article  Google Scholar 

  129. 129.

    Schmidt J, Brannstrom M, Landin-Wihelmsen K, Dahigren E. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year-follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab. 2011;96:2178–85.

    CAS  PubMed  Article  Google Scholar 

  130. 130.

    Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in woman withpolycystic ovary syndrome: a systematicreview and meta-analysis. Hum Reprod Update. 2012;18:618–37.

    CAS  PubMed  Article  Google Scholar 

  131. 131.

    Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev. 2012;33:812–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  132. 132.

    Echiburú B, Crisosto N, Maliqueo M, et al. Metabolic profile in women with polycystic ovary syndrome across adult life. Metabolism. 2016;65:776–82.

    PubMed  Article  CAS  Google Scholar 

  133. 133.

    Lo JC, Feigenbaun SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular riskprofile of diagnosedpolycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:1357–63.

    CAS  PubMed  Article  Google Scholar 

  134. 134.

    Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of nonalcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Am Hepatol. 2010;9:402–9.

    Google Scholar 

  135. 135.

    Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ. Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies. Hum Reprod Update 2012; 18:638–651.

  136. 136.

    Barry JA, Mallika MA, Hardiman PJ. Risk of endometrial, ovarian and breast cancer with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748–58.

    PubMed  PubMed Central  Article  Google Scholar 

  137. 137.

    Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome- a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92:4546–56.

    CAS  PubMed  Article  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Consortia

Corresponding author

Correspondence to José Bellver.

Ethics declarations

Conflict of interests

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bellver, J., Rodríguez-Tabernero, L., Robles, A. et al. Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet 35, 25–39 (2018). https://doi.org/10.1007/s10815-017-1047-7

Download citation

Keywords

  • Polycystic ovary syndrome
  • Childhood
  • Adolescence
  • Perimenopause
  • Fertility
  • Pregnancy complications